多発性硬化症におけるアザチオプリン治療の概要
P L Yudkin1, G W Ellison, A Ghezzi
1Department of Public Health and Primary Care, Radcliffe Infirmary, Oxford, UK.
Lancet (London, England)
|October 26, 1991
まとめ
アザチオプリンは,多発性硬化症の患者で2年間の治療後に障害の進行を軽減する小さな利点を示しました. しかし,再発率を大幅に低下させましたが,副作用に対する全般的な臨床効果は依然として議論の余地があります.
科学分野:
- 神経学 神経学とは
- 免疫学 免疫学とは
背景:
- 多発性硬化症 (MS) は,中枢神経系に影響を与える慢性自己免疫疾患です.
- 免疫抑制療法がMSの管理に使用されているが,その有効性とリスク・ベネフィット・プロフィールは継続的な評価を必要としている.
研究 の 目的:
- 多発性硬化症 (MS) の治療におけるアザチオプリンの有効性を評価する.
- MS患者における障害の進行および再発率に対するアザチオプリンの影響を評価する.
主な方法:
- 公開された盲検,ランダム化,制御試験のメタ分析.
- 7つの研究 (5つのダブルブラインド,2つのシングルブラインド) で793人の患者を含む.
- カーツケの障害状態のスコアと3年間で再発のない確率の評価.
主要な成果:
- 1年後に障害スコアの増加に有意な差はありません.
- 2歳と3歳のアザチオプリンを好む障害スコアにおける小さな持続的な利点.
- アザチオプリン群では3年間にわたって再発のない可能性が著しく高かった (相対的な確率1.97).
結論:
- アザチオプリンは,MSにおける障害の進行を遅らせることに適度な利点を示しています.
- アザチオプリンは,多発性硬化症患者の再発頻度を著しく減少させます.
- アザチオプリンの臨床的利点と,潜在的な副作用を考慮する必要があります.
関連する概念動画
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...